GH21 vs Sitneprotafib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: SHP2 · full Non-Small Cell Lung Cancer pipeline

GH21

Developed by HUYABIO International, LLC. under a licence from Suzhou Genhouse Bio Co., Ltd.

Phase 1/2 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05183243 · Phase 1 · status unknown

This is an early-stage, single-group dose-finding study with no randomization, no blinding, and no comparison group, designed only to establish a safe dose. Studies of this type do not provide controlled evidence of benefit, and no results are available yet.

Next expected readout: December 2026 · NCT05163028 (registry estimate)

No aligned efficacy figure on record for this race.

Sitneprotafib

Developed by Jacobio Pharmaceuticals and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT04720976 · Phase 1/2 · completed

The study treated participants in several open-label combination cohorts without randomization or a comparator arm; 58 participants were enrolled across dose-escalation and dose-expansion groups. Although the planned primary outcomes included clinical measures such as objective response, progression-free survival, and overall survival, no results are posted, so it is not possible to determine whether any endpoint was met.

Next expected readout: March 2027 · NCT05288205 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGH21Sitneprotafib
PFS, median—Not reported—Trial running · NCT06416410
OS, median—Not reported—Trial running · NCT06416410
ORR—Not reported—Trial running · NCT06416410
Duration of response, median—Not reported—Trial running · NCT06416410

PFS, median

GH21
—Not reported
Sitneprotafib
—Trial running · NCT06416410

OS, median

GH21
—Not reported
Sitneprotafib
—Trial running · NCT06416410

ORR

GH21
—Not reported
Sitneprotafib
—Trial running · NCT06416410

Duration of response, median

GH21
—Not reported
Sitneprotafib
—Trial running · NCT06416410
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

GH21: no structured comparison results are available for Non-Small Cell Lung Cancer.

Sitneprotafib: no structured comparison results are available for Non-Small Cell Lung Cancer.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GH21's landscape · Sitneprotafib's landscape